Oral versus Intravenous Antibiotics for Bone and Joint Infection
Este estudio ha sido identificado como potencialmente de alto impacto.
La métrica de alto impacto de OE, basada en la inteligencia artificial, estima la influencia que puede tener un artículo integrando señales procedentes tanto de la revista en la que se publica como del contenido científico del propio artículo.
Desarrollado mediante el procesamiento del lenguaje natural más avanzado, el modelo de Alto Impacto de OE predice con mayor precisión el futuro rendimiento de las citas de un estudio que el factor de impacto de la revista por sí solo.
Esto permite reconocer antes las investigaciones clínicamente significativas y ayuda a los lectores a centrarse en los artículos con más probabilidades de configurar la práctica futura.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(1):10 N Engl J Med. 2019 Jan 31;380(5): 425-436.¿Qué significa esto para mi consulta?
The results of this study suggest that oral antibiotics are non-inferior to intravenous antibiotics for the management of bone and joint infection, as measured by treatment failure. Moreover, oral antibiotics are associated with a shorter length of stay and fewer complications compared to intravenous treatment. This study was limited by the open label design and potential differences in follow-on treatment. This study challenges the widely accepted standard use of intravenous antibiotics for bone/joint infection.
Resumen del estudio
1054 patients being treated for bone or joint infection at 26 UK centers were randomized in this non-inferiority trial to receive 6 weeks of oral antibiotic therapy (n=527) or 6 weeks of intravenous antibiotic therapy (n=527). The primary outcome of interest was the rate of definite treatment failure. Secondary outcomes of interest included the rate of treatment discontinuation, catheter complications, diarrhea caused by C.difficile, serious adverse events, length of hospitalization, and patient-reported outcomes (Oxford Hip and Knee Scores [OHS; OKS]; EuroQual-5Dimension scores [EQ-5D]). Outcomes were assessed at 6 weeks, 4 months, and 1 year follow-up. Oral antibiotics were found to be non-inferior to intravenous antibiotics with regards to the risk of definitive treatment failure. The incidence of early discontinuation of treatment and catheter complications, and length of hospitalization were significantly higher in the intravenous group, however, no differences in the incidence of diarrhea or serious adverse events were observed between the two groups. EQ-5D scores and OHS scores were not significantly different between groups at 4 months and 1 year post-treatment, however, OKS scores were better in the oral group at both time points.
¿Por qué era necesario realizar este estudio ahora?
Patients with bone and joint infection require prolonged antibiotic treatment, which is frequently delivered intravenously. However, the use of intravenous antibiotics has been associated with additional complications and higher costs vs. oral antibiotics. Therefore, it is of interest to determine whether oral antibiotics can provide an non-inferior management of bone and joint infection.
¿Cuál era la pregunta principal de la investigación?
In patients with acute or chronic bone/joint infection, is oral antibiotic therapy non-inferior to intravenous antibiotic therapy with respect to treatment success, within 1 year post-randomization?
DESCARGO DE RESPONSABILIDAD
El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.
0 de 4 artículos mensuales GRATIS desbloqueados
